Ifosfamide

All ESMO 2014 abstracts with reference to ifosfamide are listed below

• 872TiP - ANZUP 1302: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours (P3BEP)
• 873TiP - A phase 2 study of paclitaxel and ifosfamide plus either cisplatin or carboplatin for patients with metastatic non-transitional cell carcinoma of the bladder and the urinary tract
• 955P - Interim analysis of an ongoing phase II trial assessing safety and efficacy of R-IDEA as salvage therapy in patients with relapsed/refractory DLBCL: An intergroup study of the society of lymphoma treatment in Japan (SoLT-J) and the west Japan hematology/oncology group (WestJHOG)
• 1413O - Zoledronate does not reduce the risk of treatment failure in osteosarcoma: results of the French multicentre OS2006 randomised trial
• 1415O - Outcome of first-line treatment of elderly advanced soft tissue sarcoma (STS) patients: a pooled analysis of eleven EORTC Soft Tissue and Bone Sarcoma Group trials
• 1420PD - May patient genetic characteristics explain heterogeneity of treatment efficacy in Ewing Sarcoma? A GWAS study
• 1438P - Trabectedin combined with Hyperthermia: Characterization of enhanced drug-efficacy in human tumor cells
• 1442P - Choi vs. RECIST assessment of tumor response in a retrospective analysis of patients (pts) receiving trabectedin (T) for advanced soft tissue sarcomas (ASTS)
• 1454P - Desmoplastic small round cell tumor (DSRCT) in adult population: Retrospective analysis
• 1461TiP - Multicenter phase 3 study of efficacy and safety of aldoxorubicin versus investigator's choice for relapsed/refractory soft tissue sarcomas